Merck & Co. has agreed to acquire Terns Pharmaceuticals for approximately $6.7 billion, the companies said today, in a deal designed to bolster the buyer’s cancer pipeline with that of Terns—led by an oral tyrosine kinase inhibitor (TKI) in an early-phase clinical trial for a form of chronic myeloid leukemia (CML). Terns’ lead and sole clinical candidate, TERN-701, is an allosteric break point clu...